US · Healthcare · Biotechnology
EPS came in at -1.08 against a street estimate of -0.74 — a miss of 45.9%.
Analysts rate Dyne Therapeutics Inc a buy (13 buy, 1 hold, 0 sell out of 14) with an average price target of $39.40.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 16.49% |
| HHG PLC | 7.31% |
| BlackRock Inc | 6.27% |
| Atlas Venture Life Science Advisors, LLC | 4.89% |
| FMR Inc | 4.77% |
| Orbis Allan Gray Ltd | 3.62% |
| State Street Corp | 3.56% |
| Vanguard Capital Management, LLC | 3.43% |
| Document | Date |
|---|---|
| Results announced · Q3 2026 | 2026-07-29 |
| Quarterly report · Q2 2026 | 2026-07-29 |
| Material agreement · Q3 2026 | 2026-07-22 |
| Company announcement · Q3 2026 | 2026-07-20 |
| Board / officer change · Q2 2026 | 2026-06-22 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Proxy statement · Q2 2026 | 2026-04-23 |
| Annual report FY2025 | 2026-03-02 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Dyne Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.